Drug Trial Radar · NCT07216313
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 30, 2025
Primary completion
Oct 20, 2025
Study completion Oct 20, 2025
Sponsor
- Lead sponsor
- Sagimet Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, 2-cohort study to evaluate the mutual DDI potential between denifanstat and resmetirom in healthy adult participants.
Conditions
- Healthy
Interventions
DenifanstatDrug
Once daily
ResmetiromDrug
Once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve during a dosing interval (tau) at steady state (AUC0-tau)Time frame: 7 days
- Maximum observed concentration at steady-state (Cmax,ss)Time frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.